Health News Releases

  • Today September 9
April 12, 2024 15:00
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed. This acquisition further enhances the vertical integration of Telix’s supply
April 09, 2024 14:28
Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
Ferring today published its 2023 Annual Report (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ferring.com%2Fwp-content%2Fuploads%2Fsites%2F16%2F2024%2F04%2FFerring-Pharmaceutic
April 09, 2024 13:19
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53923546&newsitemid=20240408059362&lan=en-US&anchor=TSE%3A4502%2FNYSE%
April 09, 2024 12:05
AACR 2024: PDC*line Pharma Presents Interim Clinical Results From Last Cohort of Patients in Phase I/II Trial with PDC*lung01 Cancer Vaccine
PDC*line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients
April 09, 2024 11:30
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar HLX14 met the p
April 04, 2024 15:10
Panda Biotech Announces Commercial Operations Have Begun at Its Flagship Panda Hemp Gin
Panda Biotech™ announced today that commercial operations have officially begun at the Panda Hemp Gin, their landmark industrial hemp processing facility in Wichita Falls, Texas. The 500000-square-foo
April 04, 2024 14:35
Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
Conformation-X Therapeutics, LLC (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.conformation-x.com&esheet=53921384&newsitemid=20240403623298&lan=en-US&anchor=Conformation-X+Ther
April 03, 2024 15:20
Merz Enters Asset Purchase Agreement With a US-Based Biotech Company
Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the tra
Peter Carbone, KBI Biopharma Chief Quality Officer (Photo: Business Wire)
April 02, 2024 13:50
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Of
March 29, 2024 10:55
Leading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG Report
PCI Pharma Services, (“PCI”) a leading global contract development and manufacturing organization (CDMO), has released its first Environmental, Social & Governance (ESG) Report (https://cts.businesswi
March 28, 2024 10:30
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Sharehold
March 27, 2024 13:30
Medisca Opens MAZ® Lab in Arizona: An Innovation and Customer Resource Center
Medisca, a global leader in personalized medicine and pharmaceutical supply chain solutions, proudly announces the opening of the Medisca MAZ Lab (https://cts.businesswire.com/ct/CT?id=smartlink&url=h
March 26, 2024 11:50
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative techno
March 22, 2024 11:00
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53912461&newsitemid=20240319911372&lan=en-US&anchor=TSE%3A4502%2FNYSE%
Rendering of Merck's new Bioprocessing Production Center in Daejeon, South Korea
March 21, 2024 13:29
Merck Invests More than € 300 Million in New Life Science Production Site in Korea
Merck invests more than € 300 million into a new Bioprocessing Production Center in Daejeon, South Korea. The new site is the largest investment by Merck's Life Science business sector in Asia-Pacific
March 19, 2024 15:19
AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aesthetic & Anti-Aging Medicine World Congress (AMWC) on M
March 19, 2024 14:55
Crown Bioscience Recognized Once Again as T+ Employer® for the Third Year in a Row
Crown Bioscience (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.crownbio.com%2F&esheet=53911141&newsitemid=20240318198586&lan=en-US&anchor=Crown+Bioscience&index=1&md5=2736454e
March 17, 2024 09:55
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) as monoth
March 15, 2024 09:45
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global
Evan L. Tzanis, COO and EVP Head of R&D, Neuraptive Therapeutics, Inc. (Photo: Business Wire)
March 14, 2024 11:20
Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data
Neuraptive Therapeutics, Inc., a pioneer in nerve repair and regeneration, is proud to announce new 24-week data from the ongoing NEUROFUSE Study for NTX-001, further solidifying the product's status
March 14, 2024 10:04
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53909424&newsitemid=20240313160788&lan=en-US&anchor=Takeda&index=1&md5=6f3040795d635d91a3047b63610ac3
March 13, 2024 11:40
Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics
Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnersh
9 Hospitals from Aster DM Healthcare network recognised (Graphic: AETOSWire)
March 12, 2024 13:45
Nine Hospitals from Aster DM Healthcare Recognized in Newsweek’s ‘World’s Best Hospitals 2024’ List
Aster DM Healthcare (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.asterdmhealthcare.com%2F&esheet=53907936&newsitemid=20240311202772&lan=en-US&anchor=Aster+DM+Healthcare&index
March 12, 2024 09:24
BIO KOREA 2024 Opens Registration for Business Partnering
BIO KOREA 2024 (https://www.biokorea.org/index.asp), jointly held by the Korea Health Industry Development Institute (https://www.khidi.or.kr/kps) (KHIDI, President: Cha Soon-do) and Chungcheongbuk-do
March 11, 2024 09:15
Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis
Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.[1]
25 per page50 per page75 per page100 per page